Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and l

Pelthos Therapeutics NYSEAMERICAN: PTHS reported second-quarter revenue growth as prescriptions for

Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $6.62 per share versus the Zacks

Pelthos Therapeutics (AMEX:PTHS) held its second-quarter earnings conference call on Thursday. Below

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the ana

Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.

DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a b

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the

Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing inno

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a b

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a bi

Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for i

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and r

Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(3.09) per share which beat the analy

ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter

DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a bi

Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing inno

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and r

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the ana

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVM

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a

Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, init

Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest

Piper Sandler analyst David Amsellem initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with

Roth Capital analyst Jonathan Aschoff maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and l

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and r

Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercial

 On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the "Company") enter

Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing inno

Lake Street analyst Thomas Flaten initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a B

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Pelthos Therapeutics (AMEX:P

Roth Capital analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with

Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the ana

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch

Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outp